Sign In
Buy IMV
$0.82
+0 (+0%)
At Close: Jul 27, 2023
Why Did B.Riley FBR Downgrade IMV’s Stock?
04:58pm, Tuesday, 31'st Mar 2020
IMV (
IMV
–
Research Report
) received a
Hold
rating and a
$3.00
price target from B.Riley FBR analyst
Mayank Mamtani
today. The company’s shares closed last Tuesday at $1.60, close to its 52-week
H.C. Wainwright Thinks IMV’s Stock is Going to Recover
03:46pm, Tuesday, 31'st Mar 2020
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on IMV (IMV – Research Report) today and set a price
IMV Inc. Announces Fourth Quarter and Full Year 2019 Financial and Operational Results
09:05pm, Monday, 30'th Mar 2020
IMV Inc. Announces Fourth Quarter and Full Year 2019 Financial and Operational Results
Two coronavirus vaccine candidates are in the clinics and 42 more are in preclinical studies, according to updated data provided by the World Health Organization on March 20.Three biopharma companies
Fly Intel: Pre-market Movers JNJ;ABT;SNY;PSTV;OMI;HEXO;AXSM;MITT
01:49pm, Monday, 30'th Mar 2020
Fly Intel: Pre-market Movers JNJ ABT SNY PSTV OMI HEXO AXSM MITT
ABT, DD among premarket gainers
01:22pm, Monday, 30'th Mar 2020
Plus Therapeutics. (NASDAQ:PSTV) +63% in-licenses novel oncology candidates.Bellerophon Therapeutics (NASDAQ:BLPH) +40% as first COVID-19 patient has been treated with the INOpulse inhaled nitric o
IMV Inc. Provides Updates on the Development of DPX-COVID-19 Vaccine and Ongoing Business and Clinical Operations
11:05am, Monday, 30'th Mar 2020
IMV Inc. (Nasdaq: IMV) (TSX: IMV), a clinical-stage biopharmaceutical company (the "Company" or "IMV"), today provided updates on the development of DPX-COVID-19, a vaccine candidate against the novel
Biotech Stock Roundup: HOTH & IMV to Develop Coronavirus Vaccines, & More
02:34pm, Wednesday, 25'th Mar 2020
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
IMV to Announce Fourth Quarter and Full Year 2019 Financial and Operational Results and Host Investor Conference Call and Webcast on March 31, 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 23.) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Be
Profit-taking pressures Moderna after Hahn comments on vaccine timeline
05:00pm, Thursday, 19'th Mar 2020
Moderna (MRNA -15.9%) slumps on more than double normal volume on the heels of comments today from FDA Commissioner Stephen Hahn (during the Coronavirus Task Force briefing) that approval of a COVID-1
Mid-Day Market Update: Crude Oil Down 15%; Biomerica Shares Spike Higher
04:27pm, Wednesday, 18'th Mar 2020
Midway through trading Wednesday, the Dow traded down 5.99% to 19,965.62 while the NASDAQ fell 4.59% to 6,997.75. The S&P also fell, dropping 5.35% to 2,394.00.
Total cases in...
Mid-Morning Market Update: Markets Open Lower; General Mills Posts Downbeat Sales
02:21pm, Wednesday, 18'th Mar 2020
Following the market opening Wednesday, the Dow traded down 4.17% to 20351.87 while the NASDAQ fell 2.96% to 7,117.79. The S&P also fell, dropping 3.85% to 2,431.81.
Total...
Canadian Micro-Cap Biopharma Imv Rips Higher On COVID-19 Vaccine Plans
02:00pm, Wednesday, 18'th Mar 2020
Micro-cap Canadian biopharma Imv Inc (NASDAQ: IMV) said Wednesday that it is advancing the clinical development of a DPX-based vaccine candidate for the coronavirus, joining a number of biotechs worki
SLS, APRN among premarket gainers
01:23pm, Wednesday, 18'th Mar 2020
Biomerica (NASDAQ:BMRA) +133% on advancement of rapid coronavirus test.IMV (NASDAQ:IMV) +55% on coronavirus vaccine plan.Vaxart (NASDAQ:VXRT) +46% on coronavirus vaccine deal.Blue Apron Holdings (N
